Suggested remit: To appraise the clinical and cost effectiveness of gefapixant within its marketing authorisation for treating refractory or unexplained chronic cough.
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
 
Status Suspended
Technology type Medicine
Decision Selected
Process TA
ID number 3789

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
01 March 2022 Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
13 May 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
20 April 2021 (14:00) Scoping workshop
01 March 2021 - 29 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual